How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story

Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patients for 12 months. This milestone moves the program closer to potential FDA filing for rexlemestrocel-L, which holds RMAT designation in a multi-million patient indication closely linked to prescription opioid use. We’ll now examine how reaching full enrollment in this RMAT-backed Phase 3 trial affects Mesoblast’s broader investment narrative and long-term prospects.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Mesoblast Investment Narrative Recap

To own Mesoblast, you need to believe its cell therapies can scale beyond a narrow pediatric GvHD niche into larger inflammatory and cardiovascular indications, while funding that journey without excessive dilution. Completing enrollment in the RMAT-backed Phase 3 chronic low back pain trial is a meaningful step toward a potential future FDA filing, but it does not change that the key near term driver remains Ryoncil execution and the core risk is still trial or regulatory setbacks that prolong losses and cash needs.

The most connected recent development is the FDA’s January feedback on rexlemestrocel L in chronic low back pain, which confirmed that a 12 month pain reduction endpoint in a 300 patient trial could support a Biologics License Application under RMAT. Taken together with today’s full enrollment milestone, this frames the CLBP program as a clearer medium term catalyst sitting alongside Ryoncil growth, while keeping investor focus on how Mesoblast manages its loss making profile until larger indications read out.

Yet investors should be aware that if the confirmatory CLBP trial disappoints or adoption is slower than hoped, the impact on future financing needs could be material...

Read the full narrative on Mesoblast (it's free!)

Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.

Uncover how Mesoblast's forecasts yield a A$3.83 fair value, a 74% upside to its current price.

Exploring Other PerspectivesASX:MSB 1-Year Stock Price Chart

Some of the lowest estimate analysts were already cautious, assuming revenue of about US$275.4 million and earnings of roughly US$48.0 million by 2029, and highlighting that any stumble in the Phase 3 chronic low back pain program could leave Mesoblast far more reliant on a single rare disease product; their more pessimistic stance is a useful reminder that reasonable people can look at the same data and reach very different conclusions.

Story Continues

Explore 11 other fair value estimates on Mesoblast - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Mesoblast research is our analysis highlighting 3 key rewards that could impact your investment decision. Our free Mesoblast research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution. The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Uncover the next big thing with 58 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MSB.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments